AZ starts phase 2/3 trial of new-variant COVID-19 vaccine

AstraZeneca and Oxford University have started dosing patients in a trial of a new version of their COVID-19 vaccine that is designed to target the beta or South African variant of the SARS-CoV-2 virus.